A Long-term Follow up Study to Evaluate the Safety and Efficacy in Transplant Recipients Treated With Modified Release Tacrolimus, FK506E (MR4), Based Immunosuppression Regimen

Trial Profile

A Long-term Follow up Study to Evaluate the Safety and Efficacy in Transplant Recipients Treated With Modified Release Tacrolimus, FK506E (MR4), Based Immunosuppression Regimen

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Heart transplant rejection; Liver transplant rejection; Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma Europe Ltd
  • Most Recent Events

    • 30 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top